Marina Takes Aim at Big Pharma Partnerships with RNAi Alternatives
February 17, 2011
Marina Takes Aim at Big Pharma Partnerships with RNAi Alternatives
"Diversity is critical to success,” Marina President and CEO Michael French said this week. Just as “no one single delivery technology is going to solve everything, no one single modality approach in the RNA and RNAi sector" is going to be the sole answer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Marina Aims for Industry Partnership in 2012, Posts Lower Q3 Losses
November 10, 2011 / Gene Silencing News - Ag-Bio Firms Increasingly Look to RNAi, microRNAs through Partnerships
May 24, 2012 / Gene Silencing News - Isis Exec Sees Antisense as Third Major Drug Platform, Says More Work to Be Done
April 19, 2012 / Gene Silencing News - Marina Preps for Additional Patient Enrollment in FAP Trial, Predicts Pharma Partnership This Year
January 26, 2012 / Gene Silencing News - As RNAi Efforts Advance, Merck Aims to Move siRNA Drug into the Clinic in 'One to Two Years'
December 8, 2011 / Gene Silencing News